(Q37799830)

23 August 2017

Challenges of drug resistance in the management of pancreatic cancer (English)

1 reference

23 August 2017

1 reference

Rizwan Sheikh

1

1 reference

23 August 2017

Naomi Walsh

2

1 reference

23 August 2017

Martin Clynes

3

1 reference

23 August 2017

Robert O'Connor

4

1 reference

23 August 2017

Ray McDermott

5

1 reference

23 August 2017

1 October 2010

1 reference

Expert Review of Anticancer Therapy

23 August 2017

1 reference

23 August 2017

10

1 reference

23 August 2017

10

1 reference

23 August 2017

1647-1661

1 reference

DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma

23 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Systemic therapy of advanced urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Nucleoside transport and its significance for anticancer drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Nucleoside transporters: molecular biology and implications for therapeutic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

bax, but not bcl-2, influences the prognosis of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Development and characterization of gemcitabine-resistant pancreatic tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Pancreatic stellate cells--role in pancreas cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma--epigenetic downregulation of caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

5-Fluorouracil: mechanisms of action and clinical strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5'-DFUR in breast cancer MCF7 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

The erbB-3 gene in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Signal transduction and oncogenesis by ErbB/HER receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Impact of molecular profiling on clinical trial design for glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Hereditary pancreatic cancer: a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.148

21 January 2018

Identifiers

DOI

10.1586/ERA.10.148

1 reference

23 August 2017

1 reference